SAGE THERAPEUTICS TRIAL

SAGE THERAPEUTICS TRIAL

The Company also previously announced its expectation that it would complete the NDA submission for MDD in the second half of 2022 and make an associated but separate NDA filing seeking the approval of zuranolone for the treatment of postpartum depression in early 2023, pending the completion and results of its SKYLARK Study, a Phase 3 placebo-controlled clinical trial evaluating the efficacy and safety of a two-week course of zuranolone 50 mg compared to placebo in women with severe PPD. Food and Drug Administration in April 2022 seeking the approval of the CompanyвЂ™s product candidate zuranolone for the treatment of major depressive disorder.

began a rolling submission of a new drug application to the U.S. Provides Zuranolone New Drug Application UpdateДЄs previously announced, Sage Therapeutics, Inc. Following the completion of the purchase, the director now directly owns 8,000 shares in the company, valued at approximately $251,600.Sage Therapeutics, Inc. The shares were purchased at an average cost of $31.45 per share, for a total transaction of $251,600.00. In other news, Director George Golumbeski bought 8,000 shares of the stock in a transaction on Thursday, May 5th. On average, analysts forecast that Sage Therapeutics will post -8.68 earnings per share for the current fiscal year. During the same period last year, the business earned ($1.64) earnings per share. 1% compared to the same quarter last year. The company's quarterly revenue was down. Sage Therapeutics had a negative net margin of 7,676.91% and a negative return on equity of 27.23%. The company had revenue of $1.58 million for the quarter, compared to analysts' expectations of $3.23 million. The biopharmaceutical company reported ($2.07) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($2.06) by ($0.01). Sage Therapeutics ( NASDAQ:SAGE - Get Rating) last announced its quarterly earnings data on Tuesday, May 3rd. The firm has a market capitalization of $2.18 billion, a P/E ratio of -4.48 and a beta of 1.57. The stock has a 50 day moving average price of $33.38 and a 200-day moving average price of $36.73. Sage Therapeutics has a 52-week low of $27.36 and a 52-week high of $79.45. Shares of NASDAQ:SAGE opened at $36.88 on Tuesday. Finally, Truist Financial dropped their target price on Sage Therapeutics from $60.00 to $40.00 and set a 'hold' rating for the company in a research note on Wednesday, March 9th. Mizuho decreased their target price on Sage Therapeutics from $41.00 to $37.00 in a research report on Wednesday, May 4th. The Goldman Sachs Group cut their price objective on shares of Sage Therapeutics from $85.00 to $73.00 and set a 'buy' rating for the company in a research report on Tuesday, May 24th. They issued a 'sell' rating for the company. started coverage on shares of Sage Therapeutics in a research report on Thursday, March 31st. SVB Leerink dropped their price target on Sage Therapeutics from $60.00 to $50.00 and set a 'market perform' rating for the company in a research report on Friday, February 25th. Several analysts recently commented on SAGE shares. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $60.32. One analyst has rated the stock with a sell recommendation, ten have assigned a hold recommendation and seven have issued a buy recommendation on the company. ( NASDAQ:SAGE - Get Rating) have been assigned an average rating of 'Hold' from the twenty-one research firms that are currently covering the company, MarketBeat Ratings reports. 7 Health Care Stocks to Buy Even if the Economy Gets Sick.7 Small-Cap Stocks that Present Long-Term Growth Opportunities.7 Transportation Stocks That Can Keep Your Portfolio Moving Forward.7 Retail Stocks That May Still Ring the Register.7 Consumer Discretionary Stocks That May Defy Expectations.7 Outdoor Living Stocks to Buy Before Investors Go Away For the Summer.7 NFT Related Stocks That Are Helping to Drive This Trend.7 Agricultural Technology Stocks to Buy as Commodity Prices Remain Volatile.7 Dividend Stocks to Buy When Safety is Your Top Priority.7 Stagflation Stocks to Help Navigate Periods of Low Growth.7 Commodities ETFs to Help Build a Hedge Against Inflation.Commercial Metals Company Is Ready To Rebound.The Q2 Earnings Season Could Be A Bloodbath.Palo Alto Networks: Pioneering AI in Cybersecurity.Honda's Stock Continues To Fly Under The Radar.eBayвЂ™s Long Term Fundamentals Are Intact If You Can Stomach Short Term Volatility.Ride Out The Recession With These Dividend Kings.The Trader's Guide to Equities Research.

Sage therapeutics